Condition

T-cell Lymphoma clinical trials and research

• 17Clinical trials
• 23NIH research projects
• 10Countries

Newest T-cell Lymphoma clinical trials

All recruiting trials (17)

• Non-Hodgkin Lymphoma Sample Collection for MRD Testing

  This study tests a blood-based and tissue-based approach to see if a molecular residual disease test can detect lingering cancer in adults with aggressive NHL who are starting standard therapy.

  Recruiting Natera, Inc. · Austin, Texas · NCT07750886

• Azacitidine and abatacept for relapsed or refractory T-cell lymphoma

  This study tests a combination of azacitidine and abatacept to see if it can shrink tumors in adults whose T-cell lymphoma has come back or not responded to treatment.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07388563

• Ruxolitinib maintenance after stem cell transplant for T‑cell lymphoma

  This phase II trial tests whether taking ruxolitinib after a stem cell transplant can lower the chance of relapse and graft‑versus‑host disease for people treated for T‑cell lymphoma.

  Recruiting at 2 sites Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio and 1 other locations · NCT07356245

• Autologous stem cell transplant combined with CD7 CAR‑T for CD7‑positive T‑cell lymphoma

  This will test whether giving a patient's own stem cell transplant together with CD7‑targeted CAR‑T cells can safely and better treat adults with CD7‑positive T‑cell lymphoma.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07106723

• Nanobody-based CAR-T therapy for relapsed T-cell leukemia and lymphoma

  This study is testing a new type of CAR-T therapy using nanobodies to see if it can help people with relapsed T-cell leukemia or lymphoma feel better and live longer.

  Recruiting Phase 1/2 Peking University People's Hospital · Beijing, Beijing Municipality · NCT06874946

• Assessing lymphoma treatment response using advanced DNA analysis

  This study is testing if analyzing DNA from blood can help doctors see how well treatment is working for patients with aggressive B-cell lymphoma without using radiation from scans.

  Recruiting National Taiwan University Hospital · Taipei · NCT06550427

• CAR-T cell therapy targeting CD5 and CD7 for T-cell leukemia and lymphoma

  This study is testing a new CAR-T cell therapy for young people with tough-to-treat T-cell leukemia and lymphoma to see if it can help them when other treatments haven't worked.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT06420076

• Improving treatment responses in children with T-cell leukemia or lymphoma

  This study is testing if adding two new drugs to standard chemotherapy can help children and young adults with T-cell leukemia or lymphoma have better treatment outcomes.

  Recruiting at 4 sites Phase 2 St. Jude Children's Research Hospital · San Diego, California and 3 other locations · NCT06390319

• Study of crushed venetoclax tablets dissolved in liquid for pediatric patients

  This study tests if crushing venetoclax tablets and mixing them with liquid helps children with blood cancers absorb the medication better and stay safe while taking it.

  Recruiting at 5 sites Children's Hospital Medical Center, Cincinnati · Aurora, Colorado and 5 other locations · NCT06131801

• Combining mogamulizumab with DA-EPOCH for aggressive T cell lymphoma treatment

  This study is testing if combining a new drug called mogamulizumab with a specific chemotherapy treatment can help people with aggressive T-cell lymphomas get better.

  Recruiting at 2 sites Phase 2 Yale University · New Haven, Connecticut and 1 other locations · NCT05996185

• Combining mogamulizumab with DA-EPOCH for aggressive T cell lymphoma treatment

  This study is testing if combining a new drug called mogamulizumab with a specific chemotherapy treatment can help people with aggressive T-cell lymphomas get better.

  Recruiting at 2 sites Phase 2 Yale University · New Haven, Connecticut and 1 other locations · NCT05996185

• Registry for individuals with T-cell lymphoma

  This study is gathering information from people with T-cell lymphoma to help researchers learn more about the disease and improve treatments.

  Recruiting at 6 sites Memorial Sloan Kettering Cancer Center · Duarte, California and 25 other locations · NCT05978141

• Combination of pembrolizumab and brentuximab for relapsed T-cell lymphoma

  This study is testing if a combination of two drugs, pembrolizumab and brentuximab, can help people with relapsed T-cell lymphoma feel better after other treatments haven't worked.

  Recruiting at 2 sites Phase 2 Yale University · New Haven, Connecticut and 1 other locations · NCT05313243

• Combination treatment for nodal T-cell lymphoma with T-follicular helper phenotype

  This study is testing a new combination of a drug called azacitidine with standard chemotherapy to see if it helps people with a specific type of nodal T-cell lymphoma feel better and have better results.

  Recruiting Phase 1/2 Samsung Medical Center · Seoul · NCT05230680

• Testing BI-1808 alone and with pembrolizumab for advanced cancers

  This study is testing a new cancer treatment called BI-1808, both alone and with another drug called pembrolizumab, to see if it is safe and effective for people with advanced cancers that haven't responded to other treatments.

  Recruiting at 18 sites Phase 1/2 BioInvent International AB · Duarte, California and 24 other locations · NCT04752826

• Testing a new treatment for relapsed T-cell non-Hodgkin lymphoma

  This study is testing a new treatment called ST-001 to see if it can help people with relapsed T-cell non-Hodgkin lymphoma feel better and have fewer side effects.

  Recruiting at 10 sites Phase 1 SciTech Development, Inc. · Scottsdale, Arizona and 9 other locations · NCT04234048

• CD4-directed CAR T-cell therapy for T-cell leukemia and lymphoma

  This study is testing a new type of CAR T-cell therapy to see if it can help people with hard-to-treat T-cell leukemia and lymphoma feel better.

  Recruiting at 5 sites Phase 1 Indiana University · Miami, Florida and 5 other locations · NCT03829540

NIH-funded research (23)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• CD2-targeted CAR-T therapy for T-cell lymphoma in a multi-center program

  A patient-focused overview of a research grant that aims to improve CAR-T cell therapy for T-cell lymphoma by exploring CD2 as a new target and enhancing allogeneic CAR-T safety features.

  NIH research Baylor College of Medicine · Houston, United States · NIH-11418402

• IL-15 and skin-homing CTCL: a targeted approach to curb skin lesions

  This grant studies how the inflammatory signal IL-15 drives CTCL T cells to settle in the skin and how blocking this pathway might help patients with this skin-limited leukemia.

  NIH research Thomas Jefferson University · Philadelphia, United States · NIH-11370320

• CD5 CAR-T therapy for T-cell lymphoma shows promise in a multi-center trial

  A phase 2 study tests a CD5-targeted CAR-T cell therapy in people with relapsed or refractory T-cell lymphoma to see if it can improve outcomes.

  NIH research March Biosciences INC · Houston, United States · NIH-11370276

• Staphylococcus aureus and CTCL: How skin bacteria may drive a blood cancer

  A doctor-scientist team is studying how certain strains of Staphylococcus aureus on the skin might influence the development and progression of cutaneous T-cell lymphoma (CTCL) in patients.

  NIH research New York University School of Medicine · New York, United States · NIH-11326309

• How a rare intestinal T‑cell lymphoma begins

  This project will test whether losing the SETD2 gene and turning on certain cancer genes causes a rare intestinal T‑cell lymphoma and makes it more sensitive to chemotherapy for people with MEITL.

  NIH research Duke University · Durham, United States · NIH-11251241

• CD5 CAR‑T treatment for relapsed or hard‑to‑treat T‑cell lymphoma

  This project is trying CD5‑targeted CAR‑T cell therapy, including faster off‑the‑shelf products, to help people with relapsed or refractory T‑cell lymphoma get better responses.

  NIH research Baylor College of Medicine · Houston, United States · NIH-11178348

• Understanding how IL-15 affects T-cell lymphoma in the skin

  This research explores how a specific signal, called IL-15, helps T-cell lymphoma cells move to and grow in the skin, aiming to find new ways to help patients with this condition.

  NIH research Thomas Jefferson University · Philadelphia, United States · NIH-11138570

• New antibody treatment for Non-Hodgkin Lymphoma and a type of skin lymphoma

  This project is testing a new antibody treatment, called BITR2101, for people with certain types of cancer, including Non-Hodgkin Lymphoma and Cutaneous T Cell Lymphoma.

  NIH research Boston Immune Technologies and Therapeutics, INC. · Winchester, United States · NIH-11131238

• Investigating how Staphylococcus aureus affects skin cancer development

  This study is looking at how a common skin bacteria called Staphylococcus aureus might affect the growth of Cutaneous T-cell lymphomas (CTCL), a type of skin cancer, by examining the bacteria found on patients' skin to find new ways to understand and treat the disease.

  NIH research New York University School of Medicine · New York, United States · NIH-11072057

• Implantable microdevice that tests cancer drugs inside T‑cell lymphoma tumors

  A tiny implant will be placed into a T‑cell lymphoma tumor to locally deliver many cancer drugs and see which ones kill tumor cells without giving full systemic doses.

  NIH research Brigham and Women's Hospital · Boston, United States · NIH-11046140

• Understanding how the tumor environment affects treatment response in T-cell lymphoma

  This study is looking at how the arrangement of cells in T-cell lymphoma tumors affects how well treatments work, with the goal of finding new ways to personalize therapy for patients.

  NIH research Brigham and Women's Hospital · Boston, United States · NIH-11032024

• Understanding how gene regulation affects cutaneous T cell lymphoma

  This study is looking at how changes in DNA can affect a type of skin cancer called cutaneous T cell lymphoma, especially a severe form known as Sezary syndrome, to help find better ways to diagnose and treat it, and patients can help us learn more about how these changes might impact their treatment.

  NIH research VA San Diego Healthcare System · San Diego, United States · NIH-11030755

• Understanding how T-cell receptors influence T-cell lymphoma progression

  This study is looking at how certain immune cells called T-cells behave in T-cell lymphoma, especially how they interact with other cells in the tumor environment, to find new ways to improve treatment options for patients.

  NIH research University of Michigan at Ann Arbor · Ann Arbor, United States · NIH-11014942

• Investigating the causes of a rare intestinal cancer

  This study is looking at a rare and tough type of cancer called Monomorphic Epitheliotropic Intestinal T-cell Lymphoma (MEITL) to understand how certain genes, especially the SETD2 gene, might play a role in its development, with the hope of finding better treatments for people affected by this condition.

  NIH research Duke University · Durham, United States · NIH-11003697

• Improving how skin samples are handled for better testing in skin lymphoma

  This study is looking at the best ways to handle skin biopsy samples from people with cutaneous T cell lymphoma to make sure the tests for their T cell genes are accurate, helping doctors diagnose and monitor treatment more effectively.

  NIH research Brigham and Women's Hospital · Boston, United States · NIH-10977523

• New treatment targeting cancer cells and their supportive environment in Non-Hodgkin Lymphoma.

  This study is testing a new treatment called BITR2101 that targets a specific part of cancer cells to help stop the growth of Non-Hodgkin Lymphoma, especially for those with Cutaneous T Cell Lymphoma, and it may be used on its own or with other therapies to improve patient outcomes.

  NIH research Boston Immune Technologies and Therapeutics, INC. · Winchester, United States · NIH-10911718

• Investigating how IL-15 affects skin cancer progression in patients with Cutaneous T-cell Lymphoma.

  This study is looking at how a protein called IL-15 affects the growth and movement of skin cancer cells in people with Cutaneous T-cell Lymphoma, using a special mouse model to find new ways to treat this condition.

  NIH research Thomas Jefferson University · Philadelphia, United States · NIH-10891650

• Targeting specific mutations in T cell lymphoma for treatment

  This study is looking for better ways to treat peripheral T cell lymphoma, an aggressive cancer, by using new technology and existing medications to target specific genetic changes in the disease, with the hope of finding more effective treatments for patients like you.

  NIH research Texas A&m University Health Science Ctr · College Station, United States · NIH-10873914

• Testing a tiny device to find the best cancer drugs for T cell lymphoma patients

  This study is testing a tiny device that can be placed right into tumors of patients with advanced skin lymphomas to find out which cancer drugs work best for them, all while keeping side effects low.

  NIH research Brigham and Women's Hospital · Boston, United States · NIH-10872242

• Improving sample handling for T cell lymphoma testing

  This study is looking to improve how skin biopsy samples are handled for people with cutaneous T cell lymphoma, so that the DNA and important markers stay safe and accurate, helping doctors make better diagnoses and treatment choices.

  NIH research Brigham and Women's Hospital · Boston, United States · NIH-10856922

• Targeted therapy for skin lymphoma using a new immunotoxin

  This study is testing a new treatment for cutaneous T-cell lymphoma (CTCL) that uses a special therapy to help your immune system fight the cancer more effectively, and it could be a great option for patients whose CTCL hasn't responded to other treatments.

  NIH research Rock Immune, INC. · Denver, United States · NIH-10850989

• Identifying genetic markers for skin lymphomas

  This study is looking at skin cancers called cutaneous T-cell lymphomas to find genetic clues that can help doctors diagnose and treat these conditions earlier and more effectively, especially for patients with specific types like mycosis fungoides and Sezary syndrome.

  NIH research Sloan-Kettering Inst Can Research · New York, United States · NIH-10812990

• Testing a new treatment for patients with relapsed or refractory peripheral T-cell lymphoma.

  This study is looking at whether a new combination of two medications, Oral Azacytidine and Romidepsin, works better than standard treatments for people with relapsed or hard-to-treat peripheral T-cell lymphoma, to see if it can help improve their chances of survival.

  NIH research University of Virginia · Charlottesville, United States · NIH-10692553

Related topics

Quick answers

How many T-cell Lymphoma clinical trials are recruiting right now?

17, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 10 countries. The most sites are in United States (12 trials), China (3 trials), Taiwan (1 trial), South Korea (1 trial), Denmark (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 6, Phase 1/2: 4, Phase 1: 3. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →